Human papillomavirus tumor-infiltrating T-regulatory lymphocytes and P53 codon 72 polymorphisms correlate with clinical staging and prognosis of oropharyngeal cancer

New Microbiologica

Volumn 36, Issue 2, 2013, Pages 133-144

  Rittà, Massimo ^a   Landolfo, Vincenzo ^a   Mazibrada, Jasenka ^b   De Andrea, Marco ^a,c   Dell'Oste, Valentina ^a   Caneparo, Valeria ^c   Peretti, Alberto ^c   Giordano, Carlo ^a   Pecorari, Giancarlo ^a   Garzaro, Massimiliano ^a   Landolfo, Santo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c Azienda Ospedaliero Universitaria Maggiore della Carità   (Italy)

Author keywords

HNSCC; HPV; P53; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

AGED; ARTICLE; CODON; FEMALE; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MORTALITY; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; PHYSIOLOGY; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; VIROLOGY;

AGED; AGED, 80 AND OVER; CODON; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

HUMAN PAPILLOMAVIRUS;

EID: 84878839810     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. BADOUAL C., HANS S., RODRIGUEZ J., ET AL. (2006). Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer. Res. 12, 465-472.
2. BADOUAL C., ROUSSEAU A., HEUDES D., ET AL. (2006). Evaluation of frozen section diagnosis in 721 parotid gland lesions. Histopathology. 49, 538-540.
3. BALKWILL F., COUSSENS L.M. (2004). Cancer: an inflammatory link. Nature. 431, 405-406.
4. BATES G.J., FOX S.B., HAN C., ET AL. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24, 5373-5380.
5. BERNARD H.U., BURK R.D., CHEN Z., VAN DOORSLAER K., HAUSEN H., DE VILLIERS E.M. (2010). Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 401, 70-79.
6. BREMNES R.M., AL-SHIBLI K., DONNEM T., ET AL. (2011). The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J. Thorac. Oncol. 6, 824-833.
7. BRINK A.A., SNIJDERS P.J., MEIJER C.J. (2007) HPV detection methods. Dis. Markers. 23, 273-281.
8. CHUNG C.H., GILLISON M.L. (2009). Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin. Cancer. Res. 15, 6758-6762.
9. CURIEL T.J., COUKOS G., ZOU L., ET AL. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949.
10. DUMONT P., LEU J.I., DELLA PIETRA A.C., 3RD, GEORGE D.L., MURPHY M. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357-365.
11. FAKHRY C., GILLISON M.L. (2006). Clinical implications of human papillomavirus in head and neck cancers. J. Clin. Oncol. 24, 2606-2611.
12. FRIDMAN W.H., GALON J., DIEU-NOSJEAN M.C., ET AL. (2011). Immune infiltration in human cancer: prognostic significance and disease control. Curr. Top. Microbiol. Immunol. 344, 1-24.
13. FRIDMAN W.H., GALON J., PAGES F., TARTOUR E., SAUTES-FRIDMAN C., KROEMER G. (2011). Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer. Res. 71, 5601-5605.
14. FUESSEL HAWS A.L., HE Q., RADY P.L., ET AL. (2004). Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J. Virol. Methods. 122, 87-93.
15. GILLESPIE M.B., RUBINCHIK S., HOEL B., SUTKOWSKI N. (2009). Human papillomavirus and oropharyngeal cancer: what you need to know in 2009. Curr. Treat. Options Oncol. 10, 296-307.
16. GILLISON M.L. (2006). Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J. Clin. Oncol. 24, 5623-5625.
17. GILLISON M.L. (2009). Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr. Opin. Oncol. 21, 439-444.
18. HAMEL N., BLACK M.J., GHADIRIAN P., FOULKES W.D. (2000). No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br. J. Cancer. 82, 757-759.
19. HANSSON B.G., ROSENQUIST K., ANTONSSON A., ET AL. (2005). Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol. 125, 1337-1344.
20. HIRAOKA N., ONOZATO K., KOSUGE T., HIROHASHI S. (2006). Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer. Res. 12, 5423-5434.
21. HIRAOKA N. (2010). Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int. J. Clin. Oncol. 15, 544-551.
22. HOFFMANN M., SCHEUNEMANN D., FAZEL A., GOROGH T., KAHN T., GOTTSCHLICH S. (2009). Human papillomavirus and p53 polymorphism in codon 72 in head and neck squamous cell carcinoma. Oncol. Rep. 21, 809-814.
23. JI X., NEUMANN A.S., STURGIS E.M., ET AL. (2008). p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis. 29, 875-879.
24. KREIMER A.R., CLIFFORD G.M., SNIJDERS P.J., ET AL. (2005). HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. Int. J. Cancer. 115, 329-332.
25. LADOIRE S., MARTIN F., GHIRINGHELLI F. (2011). Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother. 60, 909-918.
26. LI F., STURGIS E.M., CHEN X., ZAFEREO M.E., WEI Q., LI G. (2010). Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer. 116, 2350-2359.
27. LI J.F., CHU Y.W., WANG G.M., ET AL. (2009). The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int. 103, 399-405.
28. LI W., THOMPSON C.H., O'BRIEN C.J., ET AL. (2003). Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer. 106, 553-558.
29. MANNARINI L., KRATOCHVIL V., CALABRESE L., ET AL. (2009). Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngol. Ital. 29, 119-126.
30. MARIN M.C., JOST C.A., BROOKS L.A., ET AL. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25, 47-54.
31. MCWILLIAMS J.E., EVANS A.J., BEER T.M., ET AL. (2000). Genetic polymorphisms in head and neck cancer risk. Head Neck. 22, 609-617.
32. MELLIN H., DAHLGREN L., MUNCK-WIKLAND E., ET AL. (2002). Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int. J. Cancer. 102, 152-158.
33. MORK J., LIE A.K., GLATTRE E., ET AL. (2001). Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 344, 1125-1131.
34. ORSTED D.D., BOJESEN S.E., TYBJAERG-HANSEN A., NORDESTGAARD B.G. (2007). Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J. Exp. Med. 204, 1295-3101.
35. PERRONE F., MARIANI L., PASTORE E., ET AL. (2007). p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. Cancer. 109, 2461-2465.
36. PERRONE G., RUFFINI P.A., CATALANO V., ET AL. (2008). Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur. J. Cancer. 44, 1875-1882.
37. PETERSEN R.P., CAMPA M.J., SPERLAZZA J., ET AL. (2006) Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 107, 2866-2872.
38. PIM D., BANKS L. (2004). p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer. 108, 196-199.
39. RABINOWICH H., REICHERT T.E., KASHII Y., GASTMAN B.R., BELL M.C., WHITESIDE T.L. (1998). Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101, 2579-2588.
40. RAUTAVA J., KUUSKOSKI J., SYRJANEN K., GRENMAN R., SYRJANEN S. (2012). HPV genotypes and their prognostic significance in head and neck squamous cell carcinomas. J. Clin. Virol. 53, 116-120.
41. REICHERT T.E., RABINOWICH H., JOHNSON J.T., WHITESIDE T.L. (1998). Mechanisms responsible for signaling and functional defects. J. Immunother. 21, 295-306.
42. RITTÀ M., DE ANDREA M., MONDINI M., ET AL. (2009). Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. Head Neck. 31, 318-327.
43. SCHAEFER C., KIM G.G., ALBERS A., HOERMANN K., MYERS E.N., WHITESIDE T.L. (2005). Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer. 92, 913-920.
44. SCHEFFNER M., WERNESS B.A., HUIBREGTSE J.M., LEVINE A.J., HOWLEY P.M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63, 1129-1136.
45. SEREFOGLOU Z., YAPIJAKIS C., NKENKE E., VAIRAKTARIS E. (2008). Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral. Oncol. 44, 1093-1099.
46. SERVICES U.S.D.O.H.A.H., AGRICULTURE U.S.D.O. DIETARY GUIDELINES FOR AMERICANS. 6th ed. Washington, DC: U.S. Government Printing Office; 2005; 84.
47. SHEN H., ZHENG Y., STURGIS E.M., SPITZ M.R., WEI Q. (2002). P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 183, 123-130.
48. SLAUGHTER D.P., SOUTHWICK H.W., SMEJKAL W. (1953). Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 6, 963-968.
49. SOBIN L.H., GOSPODAROWICZ M.K., WITTEKIND C. TNM Classification of Malignant Tumors 7th ed. Weinheim, Germany. 2009; 302.
50. STOREY A., THOMAS M., KALITA A., HARWOOD C., GARDIOL D., MANTOVANI F., BREUER J., LEIGH I.M., MATLASHEWSKI G., BANKS L. (1998). Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 393, 229-234.
51. STRAUSS L., BERGMANN C., GOODING W., JOHNSON J.T., WHITESIDE T.L. (2007). The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13, 6301-611.
52. WANG X.I., THOMAS J., ZHANG S. (2012). Changing trends in human papillomavirus-associated head and neck squamous cell carcinoma. Ann. Diagn. Pathol. 16, 7-12.